The $36.5 billion revenue haul from weight-loss drugs has turned Eli Lilly into a pharmaceutical fortress, but Pfizer is now at the gates with a monthly shot. According to The Motley Fool, Pfizer’s new treatment, PF'3944, only requires one injection a month to achieve comparable weight loss to Lilly’s Zepbound or Novo Nordisk’s Wegovy. For the elite on a subscription body plan, the move from weekly to monthly is the ultimate luxury upgrade.

Eli Lilly isn't sitting still while its duopoly is threatened. The company recently completed a $7 billion acquisition of Kelonia, a biotech firm focused on in-vivo technology. Per PitchBook, this is a clear signal that Lilly is using its GLP-1 cash to diversify before the patent cliff hits. The race for the zero-percent body fat ratio has moved from the pharmacy to the boardroom, and the stakes are in the billions.

"This suggests that patients shouldn't simplistically be thinking, ‘I want to lose X amount of weight’," warned study leader Venky Soundararajan, per Reuters. New data suggests that while Lilly’s drugs yield greater weight loss, they might be more expensive for muscles and connective tissues. The subscription body is becoming a complex management project, requiring the same level of curation as a private art collection. The muscle loss is simply a side effect of the high-saturation lifestyle.

Lilly and Novo Nordisk have largely invented the modern anti-obesity market, but Pfizer’s monthly shot could be a game-changer for those who find weekly injections too pedestrian. According to Reuters, the study published this week highlights the hidden costs of rapid weight loss. For the Hedonist reader, the choice between these drugs is less about health and more about maintaining the perfect aesthetic with the least amount of friction.